Newron Pharmaceuticals S.p.A. (SWX:NWRN)

Switzerland flag Switzerland · Delayed Price · Currency is CHF
8.20
-0.04 (-0.49%)
May 12, 2025, 5:30 PM CET
-16.16%
Market Cap 164.48M
Revenue (ttm) 48.21M
Net Income (ttm) 14.86M
Shares Out 19.96M
EPS (ttm) 0.72
PE Ratio 11.41
Forward PE n/a
Dividend n/a
Ex-Dividend Date n/a
Volume 44,072
Average Volume 52,251
Open 8.55
Previous Close 8.24
Day's Range 7.94 - 8.55
52-Week Range 5.20 - 11.20
Beta 0.59
RSI 57.46
Earnings Date Sep 16, 2025

About Newron Pharmaceuticals

Newron Pharmaceuticals S.p.A., a biopharmaceutical company, discovers and develops novel therapies for patients with diseases of the central and peripheral nervous system in Italy and the United States. It offers Xadago (safinamide), a chemical entity for the treatment of Parkinson’s in the European Union, the United Kingdom, the United States, Latin America, Switzerland, and Japan. The company’s lead compound includes Evenamide, an add-on therapy for the treatment of Schizophrenia and treatment-resistant schizophrenia, which is in Phase III cl... [Read more]

Industry Biotechnology
Sector Healthcare
Founded 1999
Employees 22
Stock Exchange SIX Swiss Exchange
Ticker Symbol NWRN
Full Company Profile

Financial Performance

Financial numbers in EUR Financial Statements

News

Newron Pharmaceuticals reports FY results

5 weeks ago - Seeking Alpha